Parvovirus B19 infection in human pregnancy

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 118, Issue 2, 2011, Pages 175-186

  Lamont, R F ^a,b   Sobel, J D ^b   Vaisbuch, E ^a,b   Kusanovic, J P ^a,b   Mazaki Tovi, S ^a,b   Kim, S K ^a   Uldbjerg, N ^a   Romero, R ^a,b  

^a HUTZEL HOSPITAL   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Fetal anaemia; human; hydrops fetalis; nonimmune hydrops; parvovirus; pregnancy

Indexed keywords

FETUS DISEASE; HEART FAILURE; HUMAN; HUMAN PARVOVIRUS B19; HYDROPS; PARVOVIRUS INFECTION; POLYMERASE CHAIN REACTION; PREGNANCY; PRIORITY JOURNAL; REVIEW; SEROLOGY; ULTRASOUND;

ERYTHEMA INFECTIOSUM; FEMALE; FETAL DISEASES; FETAL MONITORING; HUMANS; PARVOVIRUS B19, HUMAN; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

EID: 78650338247     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/j.1471-0528.2010.02749.x     Document Type: Review

References (206)

1. Centers for Disease Control and Prevention Rashes among schoolchildren-14 states, October 4, 2001-February 27, 2002. J Am Med Assoc 2002; 287: 1389-91.
2. Valeur-Jensen AK, Pedersen CB, Westergaard T, Jensen IP, Lebech M, Andersen PK, et al. Risk factors for parvovirus B19 infection in pregnancy. J Am Med Assoc 1999; 281: 1099-105.
3. Dukes C,. On the confusion of two different diseases under the name rubella (rose-rash). Lancet 1900; 156: 89-95.
4. Cossart YE, Field AM, Cant B, Widdows D,. Parvovirus-like particles in human sera. Lancet 1975; 1: 72-3.
5. Cotmore SF, Tattersall P,. Characterization and molecular cloning of a human parvovirus genome. Science 1984; 226: 1161-5.
6. Siegl G, Bates RC, Berns KI, Carter BJ, Kelly DC, Kurstak E, et al. Characteristics and taxonomy of Parvoviridae. Intervirology 1985; 23: 61-73.
7. Gallinella G, Venturoli S, Manaresi E, Musiani M, Zerbini M,. B19 virus genome diversity: epidemiological and clinical correlations. J Clin Virol 2003; 28: 1-13.
8. Ozawa K, Kurtzman G, Young N,. Replication of the B19 parvovirus in human bone marrow cell cultures. Science 1986; 233: 883-6.
9. Servant A, Laperche S, Lallemand F, Marinho V, De Saint MG, Meritet JF, et al. Genetic diversity within human erythroviruses: identification of three genotypes. J Virol 2002; 76: 9124-34.
10. Jones MS, Kapoor A, Lukashov VV, Simmonds P, Hecht F, Delwart E,. New DNA viruses identified in patients with acute viral infection syndrome. J Virol 2005; 79: 8230-6.
11. Simmonds P, Douglas J, Bestetti G, Longhi E, Antinori S, Parravicini C, et al. A third genotype of the human parvovirus PARV4 in sub-Saharan Africa. J Gen Virol 2008; 89: 2299-302.
12. Allander T, Tammi MT, Eriksson M, Bjerkner A, Tiveljung-Lindell A, Andersson B,. Cloning of a human parvovirus by molecular screening of respiratory tract samples. Proc Natl Acad Sci USA 2005; 102: 12891-6.
13. Ergaz Z, Ornoy A,. Parvovirus B19 in pregnancy. Reprod Toxicol 2006; 21: 421-35.
14. Plummer FA, Hammond GW, Forward K, Sekla L, Thompson LM, Jones SE, et al. An erythema infectiosum-like illness caused by human parvovirus infection. N Engl J Med 1985; 313: 74-9.
15. Chorba T, Coccia P, Holman RC, Tattersall P, Anderson LJ, Sudman J, et al. The role of parvovirus B19 in aplastic crisis and erythema infectiosum (fifth disease). J Infect Dis 1986; 154: 383-93.
16. Anderson MJ, Higgins PG, Davis LR, Willman JS, Jones SE, Kidd IM, et al. Experimental parvoviral infection in humans. J Infect Dis 1985; 152: 257-65.
17. Potter CG, Potter AC, Hatton CS, Chapel HM, Anderson MJ, Pattison JR, et al. Variation of erythroid and myeloid precursors in the marrow and peripheral blood of volunteer subjects infected with human parvovirus (B19). J Clin Invest 1987; 79: 1486-92.
18. Mortimer PP, Luban NL, Kelleher JF, Cohen BJ,. Transmission of serum parvovirus-like virus by clotting-factor concentrates. Lancet 1983; 2: 482-4.
19. Bartolomei CO, Azzi A, Morfini M, Fanci R, Rossi FP,. Human parvovirus infection in haemophiliacs first infused with treated clotting factor concentrates. J Med Virol 1988; 25: 165-70.
20. Broliden K,. Parvovirus B19 infection in pediatric solid-organ and bone marrow transplantation. Pediatr Transplant 2001; 5: 320-30.
21. Anand A, Gray ES, Brown T, Clewley JP, Cohen BJ,. Human parvovirus infection in pregnancy and hydrops fetalis. N Engl J Med 1987; 316: 183-6.
22. Jordan J, Tiangco B, Kiss J, Koch W,. Human parvovirus B19: prevalence of viral DNA in volunteer blood donors and clinical outcomes of transfusion recipients. Vox Sang 1998; 75: 97-102.
23. Shneerson JM, Mortimer PP, Vandervelde EM,. Febrile illness due to a parvovirus. Br Med J 1980; 280: 1580.
24. Pattison JR, Jones SE, Hodgson J, Davis LR, White JM, Stroud CE, et al. Parvovirus infections and hypoplastic crisis in sickle-cell anaemia. Lancet 1981; 1: 664-5.
25. Anderson MJ, Cohen BJ, Schwarz T, Roggendorf M, Deinhardt F,. Human parvovirus B19 infections in United Kingdom 1984-86. Lancet 1987; 329: 738-9.
26. Anderson LJ,. Role of parvovirus B19 in human disease. Pediatr Infect Dis J 1987; 6: 711-8.
27. Mortimer PP, Cohen BJ, Buckley MM, Cradock-Watson JE, Ridehalgh MK, Burkhardt F, et al. Human parvovirus and the fetus. Lancet 1985; 2: 1012.
28. Courouce AM, Ferchal F, Morinet F, Muller A, Drouet J, Soulier JP, et al. Human parvovirus infections in France. Lancet 1984; 1: 160.
29. Okochi K, Mori R, Miyazaki M, Cohen BJ, Mortimer PP,. Nakatani antigen and human parvovirus (B19). Lancet 1984; 1: 160-1.
30. Enders M, Weidner A, Enders G,. Current epidemiological aspects of human parvovirus B19 infection during pregnancy and childhood in the western part of Germany. Epidemiol Infect 2007; 135: 563-9.
31. Kelly HA, Siebert D, Hammond R, Leydon J, Kiely P, Maskill W,. The age-specific prevalence of human parvovirus immunity in Victoria, Australia compared with other parts of the world. Epidemiol Infect 2000; 124: 449-57.
32. Nicolay N, Cotter S,. Clinical and epidemiological aspects of parvovirus B19 infections in Ireland, January 1996-June 2008. Euro Surveill 2009; 14: 1-5.
33. Mossong J, Hens N, Friederichs V, Davidkin I, Broman M, Litwinska B, et al. Parvovirus B19 infection in five European countries: seroepidemiology, force of infection and maternal risk of infection. Epidemiol Infect 2008; 136: 1059-68.
34. Stelma FF, Smismans A, Goossens VJ, Bruggeman CA, Hoebe CJ,. Occupational risk of human cytomegalovirus and parvovirus B19 infection in female day care personnel in the Netherlands; a study based on seroprevalence. Eur J Clin Microbiol Infect Dis 2009; 28: 393-7.
35. Elnifro E, Nisha AK, Almabsoot M, Daeki A, Mujber N, Muscat J,. Seroprevalence of parvovirus B19 among pregnant women in Tripoli, Libya. J Infect Dev Ctries 2009; 3: 218-20.
36. Nascimento JP, Buckley MM, Brown KE, Cohen BJ,. The prevalence of antibody to human parvovirus B19 in Rio de Janeiro, Brazil. Rev Inst Med Trop Sao Paulo 1990; 32: 41-5.
37. Anderson LJ, Tsou C, Parker RA, Chorba TL, Wulff H, Tattersall P, et al. Detection of antibodies and antigens of human parvovirus B19 by enzyme-linked immunosorbent assay. J Clin Microbiol 1986; 24: 522-6.
38. Cohen BJ, Buckley MM,. The prevalence of antibody to human parvovirus B19 in England and Wales. J Med Microbiol 1988; 25: 151-3.
39. Schwarz TF, Gurtler LG, Zoulek G, Deinhardt F, Roggendorf M,. Seroprevalence of human parvovirus B19 infection in Sao Tome and Principe, Malawi and Mascarene Islands. Zentralbl Bakteriol 1989; 271: 231-6.
40. Tolfvenstam T, Enbom M, Ghebrekidan H, Ruden U, Linde A, Grandien M, et al. Seroprevalence of viral childhood infections in Eritrea. J Clin Virol 2000; 16: 49-54.
41. de Freitas RB, Wong D, Boswell F, de Miranda MF, Linhares AC, Shirley J, et al. Prevalence of human parvovirus (B19) and rubella virus infections in urban and remote rural areas in northern Brazil. J Med Virol 1990; 32: 203-8.
42. Goldstein AR, Anderson MJ, Serjeant GR,. Parvovirus associated aplastic crisis in homozygous sickle cell disease. Arch Dis Child 1987; 62: 585-8.
43. Naides SJ,. Erythema infectiosum (fifth disease) occurrence in Iowa. Am J Public Health 1988; 78: 1230-1.
44. Vyse AJ, Andrews NJ, Hesketh LM, Pebody R,. The burden of parvovirus B19 infection in women of childbearing age in England and Wales. Epidemiol Infect 2007; 135: 1354-62.
45. Zaaijer HL, Koppelman MH, Farrington CP,. Parvovirus B19 viraemia in Dutch blood donors. Epidemiol Infect 2004; 132: 1161-6.
46. Gilbert NL, Gyorkos TW, Beliveau C, Rahme E, Muecke C, Soto JC,. Seroprevalence of parvovirus B19 infection in daycare educators. Epidemiol Infect 2005; 133: 299-304.
47. Anderson LJ, Gillespie SM, Torok TJ, Hurwitz ES, Tsou CJ, Gary GW,. Risk of infection following exposures to human parvovirus B19. Behring Inst Mitt 1990; 85: 60-3.
48. Gillespie SM, Cartter ML, Asch S, Rokos JB, Gary GW, Tsou CJ, et al. Occupational risk of human parvovirus B19 infection for school and day-care personnel during an outbreak of erythema infectiosum. J Am Med Assoc 1990; 263: 2061-5.
49. Woolf AD, Campion GV, Chishick A, Wise S, Cohen BJ, Klouda PT, et al. Clinical manifestations of human parvovirus B19 in adults. Arch Intern Med 1989; 149: 1153-6.
50. Yaegashi N, Niinuma T, Chisaka H, Watanabe T, Uehara S, Okamura K, et al. The incidence of, and factors leading to, parvovirus B19-related hydrops fetalis following maternal infection; report of 10 cases and meta-analysis. J Infect 1998; 37: 28-35.
51. Tolfvenstam T, Broliden K,. Parvovirus B19 infection. Semin Fetal Neonatal Med 2009; 14: 218-21.
52. Evans JP, Rossiter MA, Kumaran TO, Marsh GW, Mortimer PP,. Human parvovirus aplasia: case due to cross infection in a ward. Br Med J (Clin Res Ed) 1984; 288: 681.
53. Brown T, Anand A, Ritchie LD, Clewley JP, Reid TM,. Intrauterine parvovirus infection associated with hydrops fetalis. Lancet 1984; 2: 1033-4.
54. Knott PD, Welply GA, Anderson MJ,. Serologically proved intrauterine infection with parvovirus. Br Med J (Clin Res Ed) 1984; 289: 1660.
55. White DG, Woolf AD, Mortimer PP, Cohen BJ, Blake DR, Bacon PA,. Human parvovirus arthropathy. Lancet 1985; 1: 419-21.
56. Reid DM, Reid TM, Brown T, Rennie JA, Eastmond CJ,. Human parvovirus-associated arthritis: a clinical and laboratory description. Lancet 1985; 1: 422-5.
57. Van Horn DK, Mortimer PP, Young N, Hanson GR,. Human parvovirus- associated red cell aplasia in the absence of underlying hemolytic anemia. Am J Pediatr Hematol Oncol 1986; 8: 235-9.
58. Kurtzman GJ, Ozawa K, Cohen B, Hanson G, Oseas R, Young NS,. Chronic bone marrow failure due to persistent B19 parvovirus infection. N Engl J Med 1987; 317: 287-94. (Pubitemid 17100108)
59. Coulombel L, Morinet F, Mielot F, Tchernia G, Knisely AS, Shlossman P, et al. Parvovirus infection, leukaemia, and immunodeficiency. Lancet 1989; 333: 101-2.
60. Isa A, Kasprowicz V, Norbeck O, Loughry A, Jeffery K, Broliden K, et al. Prolonged activation of virus-specific CD8+ T cells after acute B19 infection. PLoS Med 2005; 2: e343.
61. Zerbini M, Musiani M, Venturoli S, Gallinella G, Gibellini D, Gentilomi G, et al. Different syndromes associated with B19 parvovirus viraemia in paediatric patients: report of four cases. Eur J Pediatr 1992; 151: 815-7.
62. Naides SJ,. Rheumatic manifestations of parvovirus B19 infection. Rheum Dis Clin North Am 1998; 24: 375-401.
63. Saarinen UM, Chorba TL, Tattersall P, Young NS, Anderson LJ, Palmer E, et al. Human parvovirus B19-induced epidemic acute red cell aplasia in patients with hereditary hemolytic anemia. Blood 1986; 67: 1411-7.
64. Centers for Disease Control. Risks associated with human parvovirus B19 infection. MMWR Morb Mortal Wkly Rep 1989; 38: 81-7.
65. Ager EA, Chin TD, Poland JD,. Epidemic erythema infectiosum. N Engl J Med 1966; 275: 1326-31.
66. Beigi RH, Wiesenfeld HC, Landers DV, Simhan HN,. High rate of severe fetal outcomes associated with maternal parvovirus b19 infection in pregnancy. Infect Dis Obstet Gynecol 2008; 2008: 524-601.
67. Young N,. Hematologic and hematopoietic consequences of B19 parvovirus infection. Semin Hematol 1988; 25: 159-72.
68. Anderson MJ, Lewis E, Kidd IM, Hall SM, Cohen BJ,. An outbreak of erythema infectiosum associated with human parvovirus infection. J Hyg (Lond) 1984; 93: 85-93.
69. Anderson MJ, Jones SE, Fisher-Hoch SP, Lewis E, Hall SM, Bartlett CLR, et al. Human parvovirus, the cause of erythema infectiosum (fifth disease)? Lancet 1983; 321: 1378.
70. Serjeant GR, Goldstein AR,. B19 virus infection and the aplastic crisis. In:, Pattison JR, editor. Parvoviruses and Human Disease. Boca Raton, FL: CRC Press, 2010. pp. 85-92.
71. Young NS, Brown KE,. Parvovirus B19. N Engl J Med 2004; 350: 586-97.
72. Broliden K, Tolfvenstam T, Norbeck O,. Clinical aspects of parvovirus B19 infection. J Intern Med 2006; 260: 285-304.
73. Silver RM, Varner MW, Reddy U, Goldenberg R, Pinar H, Conway D, et al. Work-up of stillbirth: a review of the evidence. Am J Obstet Gynecol 2007; 196: 433-44.
74. Goldenberg RL, Thompson C,. The infectious origins of stillbirth. Am J Obstet Gynecol 2003; 189: 861-73.
75. Smith MA, Shah NR, Lobel JS, Cera PJ, Gary GW, Anderson LJ,. Severe anemia caused by human parvovirus in a leukemia patient on maintenance chemotherapy. Clin Pediatr (Phila) 1988; 27: 383-6.
76. Kurtzman GJ, Cohen B, Meyers P, Amunullah A, Young NS,. Persistent B19 parvovirus infection as a cause of severe chronic anaemia in children with acute lymphocytic leukaemia. Lancet 1988; 2: 1159-62.
77. Kerr JR, O'Neill HJ, Coyle PV, Thompson W,. An outbreak of parvovirus B19 infection; a study of clinical manifestations and the incidence of fetal loss. Ir J Med Sci 1994; 163: 65-7.
78. Kinney JS, Anderson LJ, Farrar J, Strikas RA, Kumar ML, Kliegman RM, et al. Risk of adverse outcomes of pregnancy after human parvovirus B19 infection. J Infect Dis 1988; 157: 663-7.
79. Harger JH, Adler SP, Koch WC, Harger GF,. Prospective evaluation of 618 pregnant women exposed to parvovirus B19: risks and symptoms. Obstet Gynecol 1998; 91: 413-20.
80. Jensen IP, Thorsen P, Jeune B, Moller BR, Vestergaard BF,. An epidemic of parvovirus B19 in a population of 3,596 pregnant women: a study of sociodemographic and medical risk factors. BJOG 2000; 107: 637-43.
81. van Gessel PH, Gaytant MA, Vossen AC, Galama JM, Ursem NT, Steegers EA, et al. Incidence of parvovirus B19 infection among an unselected population of pregnant women in the Netherlands: a prospective study. Eur J Obstet Gynecol Reprod Biol 2006; 128: 46-9.
82. Yaegashi N, Niinuma T, Chisaka H, Uehara S, Okamura K, Shinkawa O, et al. Serologic study of human parvovirus B19 infection in pregnancy in Japan. J Infect 1999; 38: 30-5.
83. Koch WC, Adler SP,. Human parvovirus B19 infections in women of childbearing age and within families. Pediatr Infect Dis J 1989; 8: 83-7.
84. Chisaka H, Ito K, Niikura H, Sugawara J, Takano T, Murakami T, et al. Clinical manifestations and outcomes of parvovirus B19 infection during pregnancy in Japan. Tohoku J Exp Med 2006; 209: 277-83.
85. Nunoue T, Kusuhara K, Hara T,. Human fetal infection with parvovirus B19: maternal infection time in gestation, viral persistence and fetal prognosis. Pediatr Infect Dis J 2002; 21: 1133-6.
86. Nyman M, Skjoldebrand-Sparre L, Broliden K,. Non-hydropic intrauterine fetal death more than 5 months after primary parvovirus B19 infection. J Perinat Med 2005; 33: 176-8.
87. Sheikh AU, Ernest JM, O'Shea M,. Long-term outcome in fetal hydrops from parvovirus B19 infection. Am J Obstet Gynecol 1992; 167: 337-41.
88. Brennand J, Cameron A,. Fetal anaemia: diagnosis and management 1. Best Pract Res Clin Obstet Gynaecol 2008; 22: 15-29.
89. Miller E, Fairley CK, Cohen BJ, Seng C,. Immediate and long term outcome of human parvovirus B19 infection in pregnancy. Br J Obstet Gynaecol 1998; 105: 174-8.
90. Prospective study of human parvovirus (B19) infection in pregnancy. Public Health Laboratory Service Working Party on Fifth Disease. Br Med J 1990; 300: 1166-70.
91. Anderson LJ, Hurwitz ES,. Human parvovirus B19 and pregnancy. Clin Perinatol 1988; 15: 273-86.
92. Porter HJ, Khong TY, Evans MF, Chan VT, Fleming KA,. Parvovirus as a cause of hydrops fetalis: detection by in situ DNA hybridisation. J Clin Pathol 1988; 41: 381-3.
93. Anderson MJ, Khousam MN, Maxwell DJ, Gould SJ, Happerfield LC, Smith WJ,. Human parvovirus B19 and hydrops fetalis. Lancet 1988; 1: 535.
94. Franciosi RA, Tattersall P,. Fetal infection with human parvovirus B19. Hum Pathol 1988; 19: 489-91.
95. Caul EO, Usher MJ, Burton PA,. Intrauterine infection with human parvovirus B19: a light and electron microscopy study. J Med Virol 1988; 24: 55-66.
96. Porter HJ, Quantrill AM, Fleming KA,. B19 parvovirus infection of myocardial cells. Lancet 1988; 1: 535-6.
97. Sarfraz AA, Samuelsen SO, Bruu AL, Jenum PA, Eskild A,. Maternal human parvovirus B19 infection and the risk of fetal death and low birthweight: a case-control study within 35 940 pregnant women. BJOG 2009; 116: 1492-8.
98. Tolfvenstam T, Papadogiannakis N, Norbeck O, Petersson K, Broliden K,. Frequency of human parvovirus B19 infection in intrauterine fetal death. Lancet 2001; 357: 1494-7.
99. Morey AL, Keeling JW, Porter HJ, Fleming KA,. Clinical and histopathological features of parvovirus B19 infection in the human fetus. Br J Obstet Gynaecol 1992; 99: 566-74.
100. Komischke K, Searle K, Enders G,. Maternal serum alpha-fetoprotein and human chorionic gonadotropin in pregnant women with acute parvovirus B19 infection with and without fetal complications. Prenat Diagn 1997; 17: 1039-46.
101. O'Malley A, Barry-Kinsella C, Hughes C, Kelehan P, Devaney D, Mooney E, et al. Parvovirus infects cardiac myocytes in hydrops fetalis. Pediatr Dev Pathol 2003; 6: 414-20.
102. Zerbini M, Musiani M, Gentilomi G, Venturoli S, Gallinella G, Gibellini D, et al. Symptomatic parvovirus B19 infection of one fetus in a twin pregnancy. Clin Infect Dis 1993; 17: 262-3.
103. Pustilnik TB, Cohen AW,. Parvovirus B19 infection in a twin pregnancy. Obstet Gynecol 1994; 83: 834-6.
104. Foster RT Sr, Allen SR,. Differential transmission of parvovirus B19 in a twin gestation: a case report. Twin Res 2004; 7: 412-4.
105. Dickinson JE, Keil AD, Charles AK,. Discordant fetal infection for parvovirus B19 in a dichorionic twin pregnancy. Twin Res Hum Genet 2006; 9: 456-9.
106. Bekhit MT, Greenwood PA, Warren R, Aarons E, Jauniaux E,. In utero treatment of severe fetal anaemia due to parvovirus B19 in one fetus in a twin pregnancy-a case report and literature review. Fetal Diagn Ther 2009; 25: 153-7.
107. Jordan JA,. Identification of human parvovirus B19 infection in idiopathic nonimmune hydrops fetalis. Am J Obstet Gynecol 1996; 174: 37-42.
108. Gratacos E, Torres PJ, Vidal J, Antolin E, Costa J, Jimenez de Anta MT, et al. The incidence of human parvovirus B19 infection during pregnancy and its impact on perinatal outcome. J Infect Dis 1995; 171: 1360-3.
109. Rodis JF, Quinn DL, Gary GW Jr, Anderson LJ, Rosengren S, Cartter ML, et al. Management and outcomes of pregnancies complicated by human B19 parvovirus infection: a prospective study. Am J Obstet Gynecol 1990; 163: 1168-71.
110. Koch WC, Harger JH, Barnstein B, Adler SP,. Serologic and virologic evidence for frequent intrauterine transmission of human parvovirus B19 with a primary maternal infection during pregnancy. Pediatr Infect Dis J 1998; 17: 489-94.
111. Enders M, Weidner A, Zoellner I, Searle K, Enders G,. Fetal morbidity and mortality after acute human parvovirus B19 infection in pregnancy: prospective evaluation of 1018 cases. Prenat Diagn 2004; 24: 513-8.
112. Cubel RC, Garcia AG, Pegado CS, Ramos HI, Fonseca ME, Clewley JP, et al. Human parvovirus B19 infection and hydrops fetalis in Rio de Janeiro, Brazil. Mem Inst Oswaldo Cruz 1996; 91: 147-51.
113. Oliveira SA, Camacho LA, Pereira AC, Faillace TF, Setubal S, Nascimento JP,. Clinical and epidemiological aspects of human parvovirus B19 infection in an urban area in Brazil (Niteroi city area, State of Rio de Janeiro, Brazil). Mem Inst Oswaldo Cruz 2002; 97: 965-70.
114. Torok TJ,. Human parvovirus B19 infections in pregnancy. Pediatr Infect Dis J 1990; 9: 772-6.
115. Siegel G,. Biology and pathogenicity of autonomous parvoviruses. In:, Berns KI, editor. The Parvoviruses. New York: Plenum Press, 1984. pp. 297-362.
116. Weiland HT, Vermey-Keers C, Salimans MMM, Fleuren GJ, Verwey RA, Anderson MJ,. Parvovirus B19 associated with fetal abnormality. Lancet 1987; 329: 682-3.
117. Rodis JF, Hovick TJ Jr, Quinn DL, Rosengren SS, Tattersall P,. Human parvovirus infection in pregnancy. Obstet Gynecol 1988; 72: 733-8.
118. Hartwig NG, Vermeij-Keers C, Van Elsacker-Niele AM, Fleuren GJ,. Embryonic malformations in a case of intrauterine parvovirus B19 infection. Teratology 1989; 39: 295-302.
119. Guidozzi F, Ballot D, Rothberg AD,. Human B19 parvovirus infection in an obstetric population. A prospective study determining fetal outcome. J Reprod Med 1994; 39: 36-8.
120. Riipinen A, Vaisanen E, Nuutila M, Sallmen M, Karikoski R, Lindbohm ML, et al. Parvovirus B19 infection in fetal deaths. Clin Infect Dis 2008; 47: 1519-25.
121. Norbeck O, Papadogiannakis N, Petersson K, Hirbod T, Broliden K, Tolfvenstam T,. Revised clinical presentation of parvovirus B19-associated intrauterine fetal death. Clin Infect Dis 2002; 35: 1032-8.
122. Skjoldebrand-Sparre L, Tolfvenstam T, Papadogiannakis N, Wahren B, Broliden K, Nyman M,. Parvovirus B19 infection: association with third-trimester intrauterine fetal death. BJOG 2000; 107: 476-80.
123. Syridou G, Spanakis N, Konstantinidou A, Piperaki ET, Kafetzis D, Patsouris E, et al. Detection of cytomegalovirus, parvovirus B19 and herpes simplex viruses in cases of intrauterine fetal death: association with pathological findings. J Med Virol 2008; 80: 1776-82.
124. Hall SM, McCandlish AP,. Human parvovirus (B19) infection. Br J Gen Pract 1991; 41: 86.
125. Nyman M, Tolfvenstam T, Petersson K, Krassny C, Skjoldebrand-Sparre L, Broliden K,. Detection of human parvovirus B19 infection in first-trimester fetal loss. Obstet Gynecol 2002; 99: 795-8. (Pubitemid 34442457)
126. Bond PR, Caul EO, Usher J, Cohen BJ, Clewley JP, Field AM, et al. Intrauterine infection with human parvovirus. Lancet 1986; 327: 448-9.
127. Carrington D, Gilmore DH, Whittle MJ, Aitken D, Gibson AA, Patrick WJ, et al. Maternal serum alpha-fetoprotein-a marker of fetal aplastic crisis during intrauterine human parvovirus infection. Lancet 1987; 1: 433-5.
128. Woernle CH, Anderson LJ, Tattersall P, Davison JM,. Human parvovirus B19 infection during pregnancy. J Infect Dis 1987; 156: 17-20.
129. Maeda H, Shimokawa H, Satoh S, Nakano H, Nunoue T,. Nonimmunologic hydrops fetalis resulting from intrauterine human parvovirus B-19 infection: report of two cases. Obstet Gynecol 1988; 72: 482-5.
130. Young N, Harrison M, Moore J, Mortimer P, Humphries RK,. Direct demonstration of the human parvovirus in erythroid progenitor cells infected in vitro. J Clin Invest 1984; 74: 2024-32.
131. Garcia AG, Pegado CS, Cubel RC, Fonseca ME, Sloboda I, Nascimento JP,. Feto-placentary pathology in human parvovirus B19 infection. Rev Inst Med Trop Sao Paulo 1998; 40: 145-50.
132. Chisaka H, Morita E, Yaegashi N, Sugamura K,. Parvovirus B19 and the pathogenesis of anaemia. Rev Med Virol 2003; 13: 347-59.
133. Corcoran A, Doyle S,. Advances in the biology, diagnosis and host-pathogen interactions of parvovirus B19. J Med Microbiol 2004; 53: 459-75.
134. Bittencourt AL, Garcia AG,. Pathogenesis and pathology of hematogenous infections of the fetus and newborn. Pediatr Pathol Mol Med 2002; 21: 353-99.
135. Jordan JA, DeLoia JA,. Globoside expression within the human placenta. Placenta 1999; 20: 103-8.
136. Berry PJ, Gray ES, Porter HJ, Burton PA,. Parvovirus infection of the human fetus and newborn. Semin Diagn Pathol 1992; 9: 4-12.
137. von Kaisenberg CS, Bender G, Scheewe J, Hirt SW, Lange M, Stieh J, et al. A case of fetal parvovirus B19 myocarditis, terminal cardiac heart failure, and perinatal heart transplantation. Fetal Diagn Ther 2001; 16: 427-32.
138. Bultmann BD, Klingel K, Nabauer M, Wallwiener D, Kandolf R,. High prevalence of viral genomes and inflammation in peripartum cardiomyopathy. Am J Obstet Gynecol 2005; 193: 363-5.
139. Fett JD,. Viral particles in endomyocardial biopsy tissue from peripartum cardiomyopathy patients 1. Am J Obstet Gynecol 2006; 195: 330-1.
140. Jordan JA, Huff D, DeLoia JA,. Placental cellular immune response in women infected with human parvovirus B19 during pregnancy. Clin Diagn Lab Immunol 2001; 8: 288-92.
141. Jordan JA, Butchko AR,. Apoptotic activity in villous trophoblast cells during B19 infection correlates with clinical outcome: assessment by the caspase-related M30 cytodeath antibody. Placenta 2002; 23: 547-53.
142. Morgan-Capner P, Crowcroft NS,. Guidelines on the management of, and exposure to, rash illness in pregnancy (including consideration of relevant antibody screening programmes in pregnancy). Commun Dis Public Health 2002; 5: 59-71.
143. Davidkin I, Valle M, Peltola H, Hovi T, Paunio M, Roivainen M, et al. Etiology of measles- and rubella-like illnesses in measles, mumps, and rubella-vaccinated children. J Infect Dis 1998; 178: 1567-70.
144. Ramsay M, Reacher M, O'Flynn C, Buttery R, Hadden F, Cohen B, et al. Causes of morbilliform rash in a highly immunised english population. Arch Dis Child 2002; 87: 202-6.
145. Davidkin I, Jokinen S, Paananen A, Leinikki P, Peltola H,. Etiology of mumps-like illnesses in children and adolescents vaccinated for measles, mumps, and rubella. J Infect Dis 2005; 191: 719-23.
146. Oliveira MI, Curti SP, Figueiredo CA, Afonso AM, Theobaldo M, Azevedo RS, et al. Rash after measles vaccination: laboratory analysis of cases reported in Sao Paulo, Brazil. Rev Saude Publica 2002; 36: 155-9.
147. Bruu AL, Nordbo SA,. Evaluation of five commercial tests for detection of immunoglobulin M antibodies to human parvovirus B19. J Clin Microbiol 1995; 33: 1363-5.
148. Tolfvenstam T, Ruden U, Broliden K,. Evaluation of serological assays for identification of parvovirus B19 immunoglobulin M. Clin Diagn Lab Immunol 1996; 3: 147-50.
149. Butchko AR, Jordan JA,. Comparison of three commercially available serologic assays used to detect human parvovirus B19-specific immunoglobulin M (IgM) and IgG antibodies in sera of pregnant women. J Clin Microbiol 2004; 42: 3191-5.
150. Takahashi T, Ozawa K, Takahashi K, Okuno Y, Takahashi T, Muto Y, et al. DNA replication of parvovirus B19 in a human erythroid leukemia cell line (JK-1) in vitro. Arch Virol 1993; 131: 201-8.
151. Miyagawa E, Yoshida T, Takahashi H, Yamaguchi K, Nagano T, Kiriyama Y, et al. Infection of the erythroid cell line, KU812Ep6 with human parvovirus B19 and its application to titration of B19 infectivity. J Virol Methods 1999; 83: 45-54.
152. Shimomura S, Komatsu N, Frickhofen N, Anderson S, Kajigaya S, Young NS,. First continuous propagation of B19 parvovirus in a cell line. Blood 1992; 79: 18-24.
153. Cohen BJ, Mortimer PP, Pereira MS,. Diagnostic assays with monoclonal antibodies for the human serum parvovirus-like virus (SPLV). J Hyg (Lond) 1983; 91: 113-30.
154. Ferguson M, Heath A,. Report of a collaborative study to calibrate the second international standard for parvovirus B19 antibody. Biologicals 2004; 32: 207-12.
155. Kurtzman GJ, Gascon P, Caras M, Cohen B, Young NS,. B19 parvovirus replicates in circulating cells of acutely infected patients. Blood 1988; 71: 1448-54.
156. Landolsi H, Yacoubi MT, Bouslama L, Lahmar A, Trabelsi A, Hmissa S, et al. Detection of the human Parvovirus B19 in nonimmune hydrops fetalis using immunohistochemistry and nested-PCR in formalin-fixed and paraffin-embedded placenta and fetal tissues. Pathol Biol (Paris) 2009; 57: e1-7.
157. Morey AL, Porter HJ, Keeling JW, Fleming KA,. Non-isotopic in situ hybridisation and immunophenotyping of infected cells in the investigation of human fetal parvovirus infection. J Clin Pathol 1992; 45: 673-8.
158. Knoll A, Louwen F, Kochanowski B, Plentz A, Stussel J, Beckenlehner K, et al. Parvovirus B19 infection in pregnancy: quantitative viral DNA analysis using a kinetic fluorescence detection system (TaqMan PCR). J Med Virol 2002; 67: 259-66.
159. Zerbini M, Musiani M, Gentilomi G, Venturoli S, Gallinella G, Morandi R,. Comparative evaluation of virological and serological methods in prenatal diagnosis of parvovirus B19 fetal hydrops. J Clin Microbiol 1996; 34: 603-8.
160. Wattre P, Dewilde A, Subtil D, Andreoletti L, Thirion V,. A clinical and epidemiological study of human parvovirus B19 infection in fetal hydrops using PCR Southern blot hybridization and chemiluminescence detection. J Med Virol 1998; 54: 140-4.
161. Cassinotti P, Weitz M, Siegl G,. Human parvovirus B19 infections: routine diagnosis by a new nested polymerase chain reaction assay. J Med Virol 1993; 40: 228-34.
162. Carriere C, Boulanger P, Delsert C,. Rapid and sensitive method for the detection of B19 virus DNA using the polymerase chain reaction with nested primers. J Virol Methods 1993; 44: 221-34.
163. Bonvicini F, Manaresi E, Gallinella G, Gentilomi GA, Musiani M, Zerbini M,. Diagnosis of fetal parvovirus B19 infection: value of virological assays in fetal specimens. BJOG 2009; 116: 813-7.
164. Knisely AS, O'Shea PA, McMillan P, Singer DB, Magid MS,. Electron microscopic identification of parvovirus virions in erythroid-line cells in fatal hydrops fetalis. Pediatr Pathol 1988; 8: 163-70.
165. Cotmore SF, McKie VC, Anderson LJ, Astell CR, Tattersall P,. Identification of the major structural and nonstructural proteins encoded by human parvovirus B19 and mapping of their genes by procaryotic expression of isolated genomic fragments. J Virol 1986; 60: 548-57.
166. Morey AL, O'Neill HJ, Coyle PV, Fleming KA,. Immunohistological detection of human parvovirus B19 in formalin-fixed, paraffin-embedded tissues. J Pathol 1992; 166: 105-8.
167. Wright C, Hinchliffe SA, Taylor C,. Fetal pathology in intrauterine death due to parvovirus B19 infection. Br J Obstet Gynaecol 1996; 103: 133-6.
168. Quemelo PR, Lima DM, da Fonseca BA, Peres LC,. Detection of parvovirus B19 infection in formalin-fixed and paraffin-embedded placenta and fetal tissues. Rev Inst Med Trop Sao Paulo 2007; 49: 103-7.
169. Barton RB,. Parvovirus B19: twenty-five years in perspective. Pediatr Dev Pathol 1999; 2: 296-315.
170. de Jong EP, de Haan TR, Kroes AC, Beersma MF, Oepkes D, Walther FJ,. Parvovirus B19 infection in pregnancy. J Clin Virol 2006; 36: 1-7.
171. Enders M, Schalasta G, Baisch C, Weidner A, Pukkila L, Kaikkonen L, et al. Human parvovirus B19 infection during pregnancy-value of modern molecular and serological diagnostics. J Clin Virol 2006; 35: 400-6.
172. Dieck D, Schild RL, Hansmann M, Eis-Hubinger AM,. Prenatal diagnosis of congenital parvovirus B19 infection: value of serological and PCR techniques in maternal and fetal serum. Prenat Diagn 1999; 19: 1119-23.
173. Skjoldebrand-Sparre L, Nyman M, Broliden K, Wahren B,. All cases of intrauterine fetal death should be evaluated for parvovirus B19 viral deoxyribonucleic acid. Am J Obstet Gynecol 1999; 180: 1595-6.
174. Petersson K, Norbeck O, Westgren M, Broliden K,. Detection of parvovirus B19, cytomegalovirus and enterovirus infections in cases of intrauterine fetal death. J Perinat Med 2004; 32: 516-21.
175. Wolff K, Broliden K, Marsk A, Tolfvenstam T, Papadogiannakis N, Westgren M,. One stillborn and one severely hydropic twin due to parvovirus B19 infection; successful outcome of the surviving twin. Acta Obstet Gynecol Scand 1999; 78: 828-30.
176. Prowse C, Ludlam CA, Yap PL,. Human parvovirus B19 and blood products. Vox Sang 1997; 72: 1-10.
177. Lefrere JJ, Servant-Delmas A, Candotti D, Mariotti M, Thomas I, Brossard Y, et al. Persistent B19 infection in immunocompetent individuals: implications for transfusion safety. Blood 2005; 106: 2890-5.
178. Lindblom A, Isa A, Norbeck O, Wolf S, Johansson B, Broliden K, et al. Slow clearance of human parvovirus B19 viremia following acute infection. Clin Infect Dis 2005; 41: 1201-3.
179. Ross DS, Rasmussen SA, Cannon MJ, Anderson B, Kilker K, Tumpey A, et al. Obstetrician/gynecologists' knowledge, attitudes, and practices regarding prevention of infections in pregnancy. J Womens Health (Larchmt) 2009; 18: 1187-93.
180. Bizjak G, Blondin D, Hammer R, Kozlowski P, Siegmann HJ, Stressig R,. Acute infection with parvovirus B19 in early pregnancy. Ultrasound Obstet Gynecol 2009; 34: 234-5.
181. Delle CL, Buck G, Grab D, Terinde R,. Prediction of fetal anemia with Doppler measurement of the middle cerebral artery peak systolic velocity in pregnancies complicated by maternal blood group alloimmunization or parvovirus B19 infection. Ultrasound Obstet Gynecol 2001; 18: 232-6.
182. Cosmi E, Mari G, Delle CL, Detti L, Akiyama M, Murphy J, et al. Noninvasive diagnosis by Doppler ultrasonography of fetal anemia resulting from parvovirus infection. Am J Obstet Gynecol 2002; 187: 1290-3.
183. Hernandez-Andrade E, Scheier M, Dezerega V, Carmo A, Nicolaides KH,. Fetal middle cerebral artery peak systolic velocity in the investigation of non-immune hydrops. Ultrasound Obstet Gynecol 2004; 23: 442-5. (Pubitemid 38639520)
184. Borna S, Mirzaie F, Hanthoush-Zadeh S, Khazardoost S, Rahimi-Sharbaf F,. Middle cerebral artery peak systolic velocity and ductus venosus velocity in the
185. Mari G, Deter RL, Carpenter RL, Rahman F, Zimmerman R, Moise KJ Jr, et al. Noninvasive diagnosis by Doppler ultrasonography of fetal anemia due to maternal red-cell alloimmunization. Collaborative Group for Doppler assessment of the blood velocity in anemic fetuses. N Engl J Med 2000; 342: 9-14.
186. Mari G,. Middle cerebral artery peak systolic velocity for the diagnosis of fetal anemia: the untold story. Ultrasound Obstet Gynecol 2005; 25: 323-30. (Pubitemid 40547171)
187. Gray ES, Anand A, Brown T,. Parvovirus infections in pregnancy. Lancet 1986; 1: 208.
188. Brennand JE, Cameron AD,. Human parvovirus B19 in pregnancy. Hosp Med 2000; 61: 93-6.
189. Schild RL, Bald R, Plath H, Eis-Hubinger AM, Enders G, Hansmann M,. Intrauterine management of fetal parvovirus B19 infection. Ultrasound Obstet Gynecol 1999; 13: 161-6.
190. Forestier F, Tissot JD, Vial Y, Daffos F, Hohlfeld P,. Haematological parameters of parvovirus B19 infection in 13 fetuses with hydrops foetalis. Br J Haematol 1999; 104: 925-7.
191. Simms RA, Liebling RE, Patel RR, Denbow ML, Abdel-Fattah SA, Soothill PW, et al. Management and outcome of pregnancies with parvovirus B19 infection over seven years in a tertiary fetal medicine unit. Fetal Diagn Ther 2009; 25: 373-8.
192. Segata M, Chaoui R, Khalek N, Bahado-Singh R, Paidas MJ, Mari G,. Fetal thrombocytopenia secondary to parvovirus infection. Am J Obstet Gynecol 2007; 196: 61-4.
193. Cohen BJ, Kumar S,. Parvovirus B19 infection in pregnancy. Fetal Matern Med Rev 2005; 16: 123-50.
194. Smoleniec JS, Pillai M,. Management of fetal hydrops associated with parvovirus B19 infection. Br J Obstet Gynaecol 1994; 101: 1079-81.
195. von Kaisenberg CS, Jonat W,. Fetal parvovirus B19 infection. Ultrasound Obstet Gynecol 2001; 18: 280-8.
196. Fairley CK, Smoleniec JS, Caul OE, Miller E,. Observational study of effect of intrauterine transfusions on outcome of fetal hydrops after parvovirus B19 infection 1. Lancet 1995; 346: 1335-7.
197. Xu J, Raff TC, Muallem NS, Neubert AG,. Hydrops fetalis secondary to parvovirus B19 infections. J Am Board Fam Pract 2003; 16: 63-8.
198. Rodis JF, Borgida AF, Wilson M, Egan JF, Leo MV, Odibo AO, et al. Management of parvovirus infection in pregnancy and outcomes of hydrops: a survey of members of the Society of Perinatal Obstetricians. Am J Obstet Gynecol 1998; 179: 985-8.
199. Nagel HT, de Haan TR, Vandenbussche FP, Oepkes D, Walther FJ,. Long-term outcome after fetal transfusion for hydrops associated with parvovirus B19 infection. Obstet Gynecol 2007; 109: 42-7.
200. Palmer GA, Brogdon JL, Constant SL, Tattersall P,. A nonproliferating parvovirus vaccine vector elicits sustained, protective humoral immunity following a single intravenous or intranasal inoculation 1. J Virol 2004; 78: 1101-8.
201. Ballou WR, Reed JL, Noble W, Young NS, Koenig S,. Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C. 1. J Infect Dis 2003; 187: 675-8.
202. Selbing A, Josefsson A, Dahle LO, Lindgren R,. Parvovirus B19 infection during pregnancy treated with high-dose intravenous gammaglobulin. Lancet 1995; 345: 660-1.
203. Matsuda H, Sakaguchi K, Shibasaki T, Takahashi H, Kawakami Y, Furuya K,. Intrauterine therapy for parvovirus B19 infected symptomatic fetus using B19 IgG-rich high titer gammaglobulin. J Perinat Med 2005; 33: 561-3.
204. Gigler A, Dorsch S, Hemauer A, Williams C, Kim S, Young NS, et al. Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins. J Virol 1999; 73: 1974-9.
205. Alger LS,. Toxoplasmosis and parvovirus B19. Infect Dis Clin North Am 1997; 11: 55-75.
206. Enders M, Weidner A, Rosenthal T, Baisch C, Hedman L, Soderlund-Venermo M, et al. Improved diagnosis of gestational parvovirus B19 infection at the time of nonimmune fetal hydrops. J Infect Dis 2008; 197: 58-62.